NCT04592640 Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
| NCT ID | NCT04592640 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Condition | Chronic Kidney Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 9 participants |
| Start Date | 2018-09-17 |
| Primary Completion | 2027-09-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 9 participants in total. It began in 2018-09-17 with a primary completion date of 2027-09-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells
Eligibility Criteria
Inclusion Criteria: 1. 18-75 years old. 2. Clinical diagnosis of calciphylaxis, including patients with chronic kidney disease who did not or had regular dialysis (hemodialysis or peritoneal dialysis). 3. All subjects signed informed consent. Exclusion criteria: 1. Patients who refuse to sign informed consent. 2. Patients with malignant tumors or severe psychiatric disorders, or an expected survival time of less than 6 months. 3. Pregnant or lactating women of childbearing age. 4. Participation in another clinical trial with an experimental drug within 90 days prior the inclusion.
Contact & Investigator
Ningning Wang, Professor
PRINCIPAL INVESTIGATOR
The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital
Frequently Asked Questions
Who can join the NCT04592640 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Chronic Kidney Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04592640 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT04592640 currently recruiting?
Yes, NCT04592640 is actively recruiting participants. Contact the research team at wangnn@njmu.edu.cn for enrollment information.
Where is the NCT04592640 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT04592640 clinical trial?
NCT04592640 is sponsored by The First Affiliated Hospital with Nanjing Medical University. The principal investigator is Ningning Wang, Professor at The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital. The trial plans to enroll 9 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.